T3 MGen

Bengaluru, India Founded: 2021 • Age: 5 yrs
Develops proprietary technologies for immune therapeutics against diseases using AI and multidisciplinary research.

About T3 MGen

T3 MGen is a Healthcare company based in Bengaluru (India) founded in 2021 by Narendra Dnyanoba Dhele, Shankarrao Baburao Patil, and Nameirakpam Bunindro Singh. It develops proprietary technologies for immune therapeutics against diseases using AI and multidisciplinary research. It operates on a B2B and Research Collaboration model. The company has 1 employees. Its chief executive, as recorded, is Narendra Dnyanoba Dhele. T3 MGen offers products and services including Therapeutic Bioactive Peptidomers, Differentiative Biomarkers for IBD, and Small Molecules as T reg Modulators. Its focus areas include Biotechnology, Biomarkers, Inflammatory Diseases and Drug Discovery. Its legal entity in India is T-3 Molecular Genetics (T-3 Mgen) Private Limited (U73100KA2021PTC149735).

Company details

T3 Molecular Genetics is a seed-stage biotechnology company based in Bengaluru, India, focusing on solving unmet challenges in life sciences. Their multidisciplinary team of molecular biologists, data scientists, and immunologists innovates immune cell modulation technologies. They use AI, ML, and cutting-edge tools for peptide engineering, biomarker discovery, and small molecule screening to develop therapeutics for inflammatory and infectious diseases. Collaborations with institutions drive their research activities.

  • Headquarters Bengaluru, India
  • Employees 1
  • Founders Narendra Dnyanoba Dhele, Shankarrao Baburao Patil, Nameirakpam Bunindro Singh
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website t3mgen.com
  • Social LinkedIn
  • Legal Name T-3 Molecular Genetics (T-3 Mgen) Private Limited
  • Date of Incorporation 20 Jul, 2021
  • Jurisdiction Bangakore, Karnataka, India
Key Metrics
  • Annual Revenue
    ₹30,060

    FY 2023 · -60% YoY

  • Net Loss
    -₹1.6 Lakh

    FY 2023 · -540% margin

  • EBITDA
    -₹1.2 Lakh

    FY 2023 · -387% margin

  • Employee Count
    1

Products & Services of T3 MGen

T3 MGen offers a comprehensive portfolio of products and services, including Therapeutic Bioactive Peptidomers, Differentiative Biomarkers for IBD, and Small Molecules as T reg Modulators.

Therapeutic Bioactive Peptidomers
Peptide Development

Identifies and engineers biopeptides for clinical uses with AI and ML tools.

Differentiative Biomarkers for IBD
Biomarker Discovery

Targets early diagnosis of ulcerative colitis and Crohn's disease through research.

Small Molecules as T reg Modulators
Molecule Screening

Screens natural compounds to modulate T regulatory cells for disease treatment.

Board of directors of T-3 Molecular Genetics (T-3 Mgen) Private Limited (T3 MGen)

T-3 Molecular Genetics (T-3 Mgen) Private Limited is the primary company behind T3 MGen. The board of T-3 Molecular Genetics (T-3 Mgen) Private Limited currently have 3 directors; the longest-serving is Narendra Dnyanoba Dhele, appointed in 2021.

DirectorDesignationAppointedTenureEntity
Narendra Dnyanoba Dhele
DIN 09247526
Director20 Jul 20215 yrs 3 moT-3 Molecular Genetics (T-3 Mgen) Private Limited
Shankarrao Baburao Patil
DIN 09247527
Director20 Jul 20215 yrs 3 moT-3 Molecular Genetics (T-3 Mgen) Private Limited
Nameirakpam Bunindro Singh
DIN 09247528
Director20 Jul 20215 yrs 3 moT-3 Molecular Genetics (T-3 Mgen) Private Limited

People of T3 MGen

3 people are tracked at T3 MGen (3 in leadership); the tracked headcount is 1.

NameRoleGroup
Co-Founder, CEOLeadership
Co-FounderLeadership
Co-FounderLeadership
Premium access

Complete people profiles for T3 MGen

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of T3 MGen

Figures of T-3 Molecular Genetics (T-3 Mgen) Private Limited, the primary company behind T3 MGen, for FY 2023. Revenue was ₹30,060 (-60% year on year). Net loss was -₹1.6 Lakh (-540% margin). EBITDA was -₹1.2 Lakh (-387% margin).

  • ₹30,060Revenue · FY 2023 · -60% YoY
  • -₹1.6 LakhNet loss · -540% margin
  • -₹1.2 LakhEBITDA · -387% margin
  • ₹1.1 LakhPaid-up capital

Balance sheet, profit and loss, cash flow and ratios of T-3 Molecular Genetics (T-3 Mgen) Private Limited are on its company page.

Premium access

Detailed financial statements for T3 MGen

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about T3 MGen

T3 MGen was founded in 2021.

T3 MGen is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Narendra Dnyanoba Dhele is the CEO of T3 MGen, as recorded in our data. They have also founded this company.

T3 MGen has 1 employees.

The primary company behind T3 MGen, T-3 Molecular Genetics (T-3 Mgen) Private Limited, reported revenue of β‚Ή30,060 for FY 2023, down 60% year on year.

T3 Molecular Genetics is a seed-stage biotechnology company based in Bengaluru, India, focusing on solving unmet challenges in life sciences. Their multidisciplinary team of molecular biologists, data scientists, and immunologists innovates immune cell modulation technologies. They use AI, ML, and cutting-edge tools for peptide engineering, biomarker discovery, and small molecule screening to develop therapeutics for inflammatory and infectious diseases. Collaborations with institutions drive their research activities.

T3 MGen offers Therapeutic Bioactive Peptidomers, Differentiative Biomarkers for IBD, and Small Molecules as T reg Modulators.

T3 MGen operates through T-3 Molecular Genetics (T-3 Mgen) Private Limited.

The legal entities of T3 MGen currently have 3 directors, including Narendra Dnyanoba Dhele, Shankarrao Baburao Patil, Nameirakpam Bunindro Singh.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available